公开(公告)号：WO03065981A2

公开(公告)日：2003-08-14

申请号：PCT/US0200487

申请日：2002-01-09

Applicant: LILLY CO ELI ,  HEUER JOSEF GEORG ,  KIRKLY KRISTINE KAY ,  SU ERIC WEN

Inventor： HEUER JOSEF GEORG ,  KIRKLY KRISTINE KAY ,  SU ERIC WEN

IPC: A61K38/17 ,  A61P1/04 ,  A61P17/02 ,  C07K16/38 ,  A61K

CPC classification number: C07K16/38 ,  A61K38/1709

Abstract: Methods of use are provided for the treatment or prevention of poor healing or chronic wounds, skin diseases, sepsis, inflammation, immunodeficiencies, autoimmune diseases, infectious diseases, allergic diseases, and malignancies, particularly those disorders associated with the skin, by administering an LP229 polypeptide, protein, or epitope-recognizing antibody thereof to a patient in need of such therapy.

Abstract translation: 提供使用方法，通过施用LP229来治疗或预防不良的愈合或慢性伤口，皮肤疾病，败血症，炎症，免疫缺陷，自身免疫疾病，感染性疾病，过敏性疾病和恶性肿瘤，特别是与皮肤相关的疾病 多肽，蛋白质或表位识别抗体。

公开(公告)号：WO02088180A3

公开(公告)日：2003-04-24

申请号：PCT/EP0204757

申请日：2002-04-30

Applicant: SWITCH BIOTECH AG

Inventor： HALLE JOERN-PETER ,  GOPPELT ANDREAS ,  HOF PETER

IPC: G01N33/50 ,  A61K35/36 ,  A61K35/76 ,  A61K38/00 ,  A61K38/55 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P17/02 ,  A61P43/00 ,  C07K14/81 ,  C07K16/38 ,  C07K19/00 ,  C12N15/09 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/573

CPC classification number: C07K14/8121 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00 ,  C07K16/38 ,  C07K2319/00

Abstract: The invention relates to the use of alpha 1-antichymotrypsin (ACT) polypeptides according to SEQ ID No. 1 to SEQ ID No. 4 and/or nucleic acids encoding them, or an antibody or a fragment thereof directed against the polypeptide, or of a cell which is expressing the polypeptide or a nucleic acid encoding it, for diagnosis, treatment and/or prevention of diabetes-associated and/or arterial wounds which heal poorly and for identifying pharmacologically active substances which exert an influence on the expression or function, particularly the activity of ACT.

Abstract translation: 本发明涉及根据SEQ ID No.1至SEQ ID No.4的α1-抗胰凝乳蛋白酶（ACT）多肽和/或编码它们的核酸或针对多肽的抗体或其片段，或 正在表达多肽或编码它的核酸的细胞，用于诊断，治疗和/或预防不利地愈合的糖尿病相关和/或动脉创伤，并用于鉴定对表达或功能产生影响的药理学活性物质， 特别是ACT的活动。

公开(公告)号：WO0164888A3

公开(公告)日：2002-02-28

申请号：PCT/US0106295

申请日：2001-02-27

Applicant: ZYMOGENETICS INC

Inventor： SHEPPARD PAUL O

IPC: C07K14/81 ,  C12N1/21 ,  C12N15/15 ,  C07K16/38 ,  C07K19/00 ,  C12N5/10

CPC classification number: C07K14/8114 ,  C07K2319/00

Abstract: Proteinase inhibitors comprising a Kunitz domain are disclosed. The Kunitz domain comprises a motif of amino acid residues as shown in SEQ ID NO:7, wherein the sequence is at least 90 % identical to residues 328 through 378 or 386 through 436 of SEQ ID NO:2. Also disclosed are methods for producing the proteinase inhibitors, and expression vectors and cultured cells that are useful within the methods. The proteinase inhibitors may be used as components of cell culture media, in protein purification, and in certain therapeutic and diagnostic applications.

Abstract translation: 公开了包含Kunitz结构域的蛋白酶抑制剂。 Kunitz结构域包含如SEQ ID NO：7所示的氨基酸残基的基序，其中该序列与SEQ ID NO：2的残基328至378或386至436至少90％相同。 还公开了用于生产在该方法中有用的蛋白酶抑制剂，表达载体和培养细胞的方法。 蛋白酶抑制剂可用作细胞培养基的组分，蛋白质纯化以及某些治疗和诊断应用。

公开(公告)号：WO01064888A2

公开(公告)日：2001-09-07

申请号：PCT/US2001/006295

申请日：2001-02-27

IPC: C07K14/81 ,  C12N1/21 ,  C12N15/15 ,  C07K16/38 ,  C07K19/00 ,  C12N5/10

CPC classification number: C07K14/8114 ,  C07K2319/00

Abstract: Proteinase inhibitors comprising a Kunitz domain are disclosed. The Kunitz domain comprises a motif of amino acid residues as shown in SEQ ID NO:7, wherein the sequence is at least 90 % identical to residues 328 through 378 or 386 through 436 of SEQ ID NO:2. Also disclosed are methods for producing the proteinase inhibitors, and expression vectors and cultured cells that are useful within the methods. The proteinase inhibitors may be used as components of cell culture media, in protein purification, and in certain therapeutic and diagnostic applications.

Abstract translation: 公开了包含Kunitz结构域的蛋白酶抑制剂。 Kunitz结构域包含如SEQ ID NO：7所示的氨基酸残基的基序，其中该序列与SEQ ID NO：2的残基328至378或386至436至少90％相同。 还公开了用于生产在该方法中有用的蛋白酶抑制剂，表达载体和培养细胞的方法。 蛋白酶抑制剂可用作细胞培养基的组分，蛋白质纯化以及某些治疗和诊断应用。

公开(公告)号：WO01059100A2

公开(公告)日：2001-08-16

申请号：PCT/US2000/034756

申请日：2000-12-19

IPC: G01N33/50 ,  A01N37/18 ,  A01N43/04 ,  A61K31/70 ,  A61K31/7088 ,  A61K35/76 ,  A61K38/00 ,  A61K38/17 ,  A61K38/57 ,  A61K45/00 ,  A61K45/06 ,  A61K48/00 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/14 ,  A61P13/12 ,  A61P17/02 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61P35/04 ,  A61P41/00 ,  A61P43/00 ,  C07H21/04 ,  C07K14/00 ,  C07K14/47 ,  C07K14/81 ,  C07K16/00 ,  C07K16/18 ,  C07K16/38 ,  C07K19/00 ,  C12N20060101 ,  C12N1/19 ,  C12N1/21 ,  C12N5/00 ,  C12N5/02 ,  C12N5/10 ,  C12N7/00 ,  C12N15/00 ,  C12N15/09 ,  C12N15/10 ,  C12N15/12 ,  C12N15/62 ,  C12N15/63 ,  C12N15/70 ,  C12N15/74 ,  C12N15/86 ,  C12P21/02 ,  C12P21/06 ,  C12P21/08 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/53 ,  G01N33/567 ,  G01N33/68

CPC classification number: C07K14/4705 ,  A61K38/00 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/6893 ,  G01N2800/164 ,  G01N2800/32 ,  G01N2800/325

Abstract: Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract translation: 公开了用于刺激或抑制哺乳动物（包括人）中的血管发生和/或心血管化的组合物和方法。 药物组合物基于已被鉴定为一种或多种这些用途的多肽或其拮抗剂。 可以通过本文组合物诊断，预防或治疗的疾病包括创伤，例如创伤，各种癌症和血管障碍，包括动脉粥样硬化和心脏肥大。 此外，本发明涉及新型多肽和编码那些多肽的核酸分子。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子，与本发明的多肽结合的抗体以及本发明的多肽的制备方法 发明。

公开(公告)号：WO01051085A1

公开(公告)日：2001-07-19

申请号：PCT/US2001/001158

申请日：2001-01-12

IPC: A61K31/00 ,  A61K31/401 ,  A61K31/417 ,  A61K31/585 ,  A61K38/00 ,  A61K38/55 ,  A61P11/06 ,  C07K16/38 ,  A61K39/395 ,  A61K31/70 ,  A61K31/7088

CPC classification number: A61K31/711 ,  A61K31/00 ,  A61K31/401 ,  A61K31/417 ,  A61K31/585 ,  A61K38/556 ,  A61K2039/505 ,  C07K16/38

Abstract: Plasminogen activator inhibitor-1 (PAI-1) antagonists can be used in the treatment of asthma and chronic obstructive pulmonary disease.

Abstract translation: 纤溶酶原激活物抑制剂-1（PAI-1）拮抗剂可用于治疗哮喘和慢性阻塞性肺疾病。

公开(公告)号：WO01038534A2

公开(公告)日：2001-05-31

申请号：PCT/US2000/032100

申请日：2000-11-20

IPC: C07K14/81 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N15/15 ,  C07K16/38 ,  C12N5/10 ,  C12Q1/68 ,  G01N33/68

CPC classification number: C07K14/8121

Abstract: Members of the serine protease family play a role in carefully controlled processes, such as blood coagulation, fibrinolysis, complement activation, fertilization, and hormone production. The enzymatic activity of the serine proteases is regulated in part by serpins, serine protease inhibitors. Serpin dysfunction is associated with various disorders, including emphysema, blood clotting disorders, cirrhosis, Alzheimer disease, and Parkinson disease. Zserp 11 is a new member of the serine protease inhibitor family.

Abstract translation: 丝氨酸蛋白酶家族的成员在精心控制的过程中起作用，例如血液凝固，纤维蛋白溶解，补体激活，受精和激素生成。 丝氨酸蛋白酶的酶活性部分由丝氨酸蛋白酶抑制剂丝氨酸蛋白酶抑制剂调节。 丝氨酸蛋白酶功能障碍与各种疾病有关，包括肺气肿，凝血障碍，肝硬化，阿尔茨海默病和帕金森病。 Zserp 11是丝氨酸蛋白酶抑制剂家族的新成员。

公开(公告)号：WO99058569A1

公开(公告)日：1999-11-18

申请号：PCT/AU1999/000343

申请日：1999-05-07

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/43 ,  A61K39/44 ,  A61K47/48 ,  A61P7/04 ,  A61P35/00 ,  A61P43/00 ,  C07K14/46 ,  C07K14/81 ,  A61K38/17 ,  A61K38/36 ,  C07H21/04 ,  C07K16/38

CPC classification number: C07K14/46 ,  A61K47/6811 ,  A61K47/6843

Abstract: The invention provides novel single stage competitive inhibitors of plasmin from the Australian brown snake Pseudonaja textilis textilis. The invention also features polynucleotides and polynucleotide homologues encoding these inhibitors. Pharmaceutical compositions containing the plasmin inhibitors of the invention are also disclosed as well as methods useful for treatment of blood loss.

Abstract translation: 本发明提供了来自澳大利亚棕色蛇假丝酵母的新型单阶段竞争性抑制剂。 本发明还涉及编码这些抑制剂的多核苷酸和多核苷酸同系物。 还公开了含有本发明的纤溶酶抑制剂的药物组合物以及可用于治疗失血的方法。

公开(公告)号：WO9812334A3

公开(公告)日：1998-07-23

申请号：PCT/US9716123

申请日：1997-09-19

Applicant: REED GUY L ,  HARRIS LINDA ,  BAJORATH JURGEN ,  MATSUEDA GARY ,  HSU MEI-YIN ,  NOVOTNY JIRI

Inventor： REED GUY L ,  HARRIS LINDA ,  BAJORATH JURGEN ,  MATSUEDA GARY ,  HSU MEI-YIN ,  NOVOTNY JIRI

IPC: G01N33/53 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P7/02 ,  A61P9/10 ,  A61P11/00 ,  C07K16/18 ,  C07K16/38 ,  C07K16/46 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  C12R1/91 ,  G01N33/86 ,  C12N15/62

CPC classification number: G01N33/86 ,  A61K38/00 ,  A61K39/395 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/38 ,  C07K2317/24 ,  C07K2319/00 ,  A61K2300/00

Abstract: An immunologic molecule, wherein said immunologic molecule does not compete with monoclonal antibody RWR and is capable of binding to and inhibit both (1) human and nonhuman circulating alpha-2-antiplasmins and (2) human and nonhuman fibrin cross-linked alpha-2-antiplasmins selected from the group consisting of a chimeric antibody, a humanized antibody, and a single chain antibody. The invention further relates to nucleic acid molecules encoding said immunologic molecules. 00000

Abstract translation: 一种免疫学分子，其中所述免疫分子不与单克隆抗体RWR竞争并且能够结合并抑制（1）人和非人循环α-2-抗血浆素和（2）人和非人纤维蛋白交联的α-2 - 抗自由基选自嵌合抗体，人源化抗体和单链抗体。 本发明还涉及编码所述免疫分子的核酸分子。 00000

公开(公告)号：WO9604378A3

公开(公告)日：1996-03-14

申请号：PCT/US9509464

申请日：1995-07-25

Applicant: CHIRON CORP

Inventor： INNIS MICHAEL A ,  CREASEY ALBA A

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/55 ,  A61K39/395 ,  A61P7/02 ,  A61P31/04 ,  C07K14/81 ,  C07K16/38 ,  C07K19/00 ,  C12N1/19 ,  C12N15/15 ,  C12P21/02 ,  C12P21/08 ,  A61K38/57

CPC classification number: C07K14/8114 ,  A61K38/00 ,  C07K2319/00

Abstract: Chimeric proteins possessing Kunitz-type domain 1 of TFPI-2 and Kunitz-type domain 2 of TFPI are disclosed, as are muteins of TFPI and TFPI-2. Nucleic acid sequences, expression vectors and transformed host cells encoding and capable of producing the disclosed chimeric proteins and muteins are also disclosed. Finally, methods for prevention and treatment of septic shock using the chimeric proteins and muteins are disclosed.

Abstract translation: 公开了具有TFPI-2的Kunitz型结构域1和TFPI的Kunitz型结构域2的嵌合蛋白，以及TFPI和TFPI-2的突变蛋白。 还公开了编码和能够产生所公开的嵌合蛋白和突变蛋白的核酸序列，表达载体和转化的宿主细胞。 最后，公开了使用嵌合蛋白和突变蛋白预防和治疗感染性休克的方法。